CDx Partnership Program

About HAWK Biosystems

HAWK Biosystems is a private, pre-revenue diagnostics company founded in 2018, pioneering a novel spatial biology platform. Its core technology, QF-Pro®, uses an amplified FRET-FLIM assay to quantify functional protein interactions and modifications at nanoscopic resolution in FFPE tissues, a capability unachievable with existing methods. The company is initially targeting the immuno-oncology market to improve immunotherapy patient selection and has established partnership programs for development and commercialization. HAWK operates as a platform technology provider with a clear path toward companion diagnostic development.

Therapeutic Areas

Other Various (Partner-dependent) Drugs